Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants

Hum Vaccin Immunother. 2018 Jun 3;14(6):1444-1452. doi: 10.1080/21645515.2018.1438794. Epub 2018 Apr 9.

Abstract

Background: This study aimed to evaluate the cost-effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV-13) compared to a no vaccination strategy in Chinese infants.

Methods: A Markov process model was developed to examine the outcomes of PCV-13 against a no vaccination strategy using data and assumptions adapted for relevance to China. Outcomes over a lifetime horizon are presented. One-way and probabilistic sensitivity analyses were performed to determine the uncertainty.

Results: Compared to no vaccination, a PCV-13 vaccination program would provide a gain of 0.009 additional quality-adjusted life years (QALYs) per subject. From the health care and societal perspectives, the incremental costs per QALY were $20,709 and 18,483, respectively. When herd effect was included, the cost effectiveness of the PCV-13 vaccination strategy was notably improved. The lower price of PCV-13 will improve the cost-effectiveness.

Conclusions: The PCV-13 vaccination is likely to be cost-effective at the current Chinese prices and ceiling threshold ($8,382).

Keywords: Chinese infant; Cost-effectiveness analysis; Decision model; PCV-13; pneumococcal disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Asian People
  • Child
  • Child, Preschool
  • China / epidemiology
  • Cost-Benefit Analysis*
  • Female
  • Humans
  • Infant
  • Male
  • Middle Aged
  • Models, Statistical
  • Pneumococcal Infections / economics*
  • Pneumococcal Infections / epidemiology
  • Pneumococcal Infections / prevention & control*
  • Pneumococcal Vaccines / administration & dosage*
  • Pneumococcal Vaccines / economics*
  • Quality-Adjusted Life Years
  • Vaccination / economics*
  • Young Adult

Substances

  • 13-valent pneumococcal vaccine
  • Pneumococcal Vaccines

Grants and funding

This study was supported by the Fourth Round of the Three-year Action Plan on Public Health Discipline and Talent Program (Evidence-based Public Health and Health Economics, No. 15GWZK0901) from Shanghai Health and Family Planning Commission. The funding agencies had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation.